LB Pharmaceuticals

LBRX · NASDAQ

$41.00+$2.19 (+5.64%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $38.81

LBRX analyst rating

BuyConsensus of 9 analysts over the last 12 months. 89% rate it a buy.

Strong buy0
Buy8
Hold1
Underperform0
Sell0

12-month price target · 11 analysts

Average $56.21 (+37.1% upside)

Low: $37.37
Now: $41.00
High: $81.90

Upgrades and downgrades

The latest rating actions, newest first

LBRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Oct 9, 2026	Initiates	Buy	$65.00	42%
Guggenheim	Oct 6, 2026	Initiates	Buy	$80.00	17%
Roth Capital	Oct 5, 2026	Downgrade	Buy → Neutral	$37.00 → $35.00	44%
Needham	Oct 2, 2026	Initiates	Buy	$68.00	47%
HC Wainwright & Co.	Aug 24, 2026	Maintains	Buy	$45.00 → $60.00	43%
BMO Capital	Aug 12, 2026	Maintains	Outperform	$46.00 → $54.00	25%
HC Wainwright & Co.	Aug 3, 2026	Maintains	Buy	$45.00	43%
BMO Capital	Jul 21, 2026	Initiates	Outperform	$46.00	25%
Wolfe Research	Jul 7, 2026	Initiates	Outperform	$45.00	60%
HC Wainwright & Co.	Apr 27, 2026	Initiates	Buy	$45.00	43%

The case for and against

Updated Oct 14, 2026

Bull case

LB Pharmaceuticals is attractive because LB-102 is a re-engineered amisulpride with materially better blood-brain barrier penetration, enabling once-daily dosing at 50-100 mg versus >600 mg/day for amisulpride, while preserving a clinically validated D2/D3/5-HT7 profile. In schizophrenia, NOVA-1 showed statistically significant PANSS improvement across all doses, with effect sizes of 0.41-0.83, low EPS, limited sedation, and supportive cognitive and negative-symptom signals, all of which strengthen the case for a differentiated branded antipsychotic. Beyond schizophrenia, the pipeline adds meaningful upside through bipolar depression and adjunctive MDD, while pro forma cash of about $478M funds operations beyond 2Q29 and supports multiple readouts.

Bear case

LB Pharmaceuticals is viewed negatively because its lead asset, LB-102, still faces major clinical and regulatory execution risk after a larger Phase 3 study showed reduced efficacy, with only the higher dose meeting the primary endpoint and optionality narrowing for lower doses. The investment case is also weakened by safety and differentiation concerns, including observed weight gain above a level some clinicians begin to adjust therapy, along with prolactin elevation and QTc concerns, while the broader antipsychotic market remains crowded and new competitors could erode uptake. Financially, the company remains dependent on external funding until cash flow positive, and the cited valuation assumes only 70% probability of approval in schizophrenia and 50% in bipolar I depression, underscoring meaningful downside if NOVA-2 or the Phase 2 bipolar trial disappoint.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.